Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

  • ID: 3715493
  • Report
  • Region: Global
  • 179 pages
  • GBI Research
1 of 4
Global Viral Infections Market to Reach $117.6 Billion by 2021
Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

Summary

Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host. As viral pathogens are exceptionally diverse, the morbidity associated with viral infections varies significantly depending on the virus in question.

This report covers all viral infections, although particular focus is given to four key indications within this disease cluster: Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and influenza. The global viral infections market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021. Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.

Scope

The viral infections market is large and growing rapidly
- How do epidemiology trends differ among the key indications?
- What therapeutic options exist for preventing and treating viral infections?
- Which products and companies dominate the market?
The pipeline is innovative and diverse
- What is the proportion of early- to late-stage pipeline products?
- Which molecular targets are most prominent within the pipeline?
- How do the key indications differ in terms of molecule type?
Considerable market growth is anticipated throughout 2021
- Which products will contribute to this growth most significantly?
- Will the current market leaders retain their dominance over the forecast period?
Deal values for licensing and co-development deals range considerably
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?

Reasons to buy

This report will allow you to -
- Examine the current clinical and commercial landscape by considering disease pathogenesis, treatment options and key marketed products.
- Appreciate how the four key indications - HIV, HCV, HBV and influenza - differ in terms of epidemiology, symptoms and co-morbidities and complications.
- Identify trends and developments, in terms of molecule type and molecular target, within the overall viral infections pipeline, as well as for each of the four key indications.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
- Recognize how the evolving treatment landscape will drive market growth to 2021 and understand the contributions that different products, molecular targets and companies will make to this growth.
- Understand how strategic consolidations have shaped the current pipeline and marketed product landscapes.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Introduction
2.2 Human Immunodeficiency Virus (HIV)
2.2.1 Overview
2.2.2 Symptoms
2.2.3 Co-morbidities and Complications
2.2.4 Epidemiology
2.3 Hepatitis C Virus
2.3.1 Overview
2.3.2 Symptoms
2.3.3 Co-morbidities and Complications
2.3.4 Epidemiology
2.4 Hepatitis B Virus
2.4.1 Overview
2.4.2 Symptoms
2.4.3 Co-morbidities and Complications
2.4.4 Epidemiology
2.5 Influenza
2.5.1 Overview
2.5.2 Symptoms
2.5.3 Co-morbidities and Complications
2.5.4 Epidemiology
2.6 Etiology and Pathogenesis of Viral Infections
2.7 Treatment for Viral Infections
2.7.1 Vaccines
2.7.2 Antiviral Agents
3 Marketed Products
3.1 Multiple Indications
3.1.1 Viread - Gilead
3.1.2 Epivir/Epivir-HBV - ViiV Healthcare
3.1.3 Pegasys - F. Hoffmann La Roche
3.2 Human Immunodeficiency Virus (HIV)
3.2.1 Truvada - Gilead
3.2.2 Atripla - Gilead
3.2.3 Stribild - Gilead
3.2.4 Tivicay - ViiV Healthcare
3.2.5 Triumeq - ViiV Healthcare
3.2.6 Genvoya - Gilead
3.3 Hepatitis C Virus (HCV)
3.3.1 Olysio - Janssen
3.3.2 Sovaldi and Harvoni - Gilead
3.3.3 Zepatier - Merck and Co.
3.4 Hepatitis B Virus
3.4.1 Baraclude - Bristol-Myers Squibb
3.5 Influenza Virus
3.5.1 Tamiflu - Roche
4 Pipeline
4.1 Overview
4.2 Pipeline Products by Stage of Development and Molecule Type
4.3 Pipeline Products by Molecular Target
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Cumulative Clinical Trial Size
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Sofosbuvir in Combination with Velpatasvir - Gilead
4.5.2 Tenofovir alafenamide fumarate - Gilead
4.5.3 Descovy - Gilead
4.5.4 Cobicistat, darunavir, emtricitabine and TAF - Johnson & Johnson
4.5.5 Beclabuvir hydrochloride - Bristol-Myers Squibb
4.5.6 V-212 - Merck
5 Multi-scenario Market Forecast to 2021
5.1 Revenues Analysis by Molecular Target
5.1.1 Reverse Transcriptase
5.1.2 Nonstructural Protein 5B Polymerase and Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A
5.1.3 HIV Integrase
5.1.4 Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase
5.1.5 NS3-4A Protease/Nonstructural Protein 5A
5.2 Revenue and Market Share Analysis by Company
5.2.1 Gilead Sciences - Monopolization of Market to Continue Throughout 2021
5.2.2 Merck - Uptake of Zepatier and Gardasil 9 to Encourage Strong Growth
5.2.3 GlaxoSmithKline - Tivicay and Triumeq to Propel Company Revenues
5.2.4 Johnson and Johnson - Market Share to Dwindle as Sales for Prezista and Olysio Decline
5.2.5 Bristol-Myers Squibb - Marginalization Due to Patent Expirations
6 Company Analysis and Positioning
6.1 Company Landscape
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Value, Year and Indication
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.2 Co-development Deals
7.2.1 Deals by Region, Value, Year and Indication
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Molecular Target and Value
8 Appendix
8.1 References
8.2 Abbreviations
8.3 Table of All Pipeline Products
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape
8.5 Contact Us
8.6 Disclaimer

1.1 List of Tables
Table 1: Common Routes of Viral Entry
Table 2: Viral Infections Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
Table 3: Viral Infections Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016
Table 4: Table of All Pipeline Products

1.2 List of Figures
Figure 1: Viral Infections Therapeutics Market, Major Markets, HIV Prevalence (‘000), 2014-2021
Figure 2: Viral Infections Therapeutics Market, Major Markets, HCV Prevalence (‘000), 2014-2021
Figure 3: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Viread ($m), 2006-2021
Figure 4: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Epivir/Epivir-HBV ($m), 2006-2021
Figure 5: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Pegasys ($m), 2006-2021
Figure 6: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Truvada ($bn), 2006-2021
Figure 7: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Atripla ($bn), 2006-2021
Figure 8: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Stribild ($bn), 2012-2021
Figure 9: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Tivicay ($bn), 2013-2021
Figure 10: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Triumeq ($bn), 2015-2021
Figure 11: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Genvoya ($bn), 2016-2021
Figure 12: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Olysio ($m), 2013-2021
Figure 13: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Sovaldi and Harvoni ($bn), 2013-2021
Figure 14: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Zepatier ($bn), 2016-2021
Figure 15: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Baraclude ($m), 2006-2021
Figure 16: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Tamiflu ($m), 2006-2021
Figure 17: Overall Pharmaceutical Industry Pipeline by Therapy Area, Global, 2016
Figure 18: Viral Infections Therapeutics Market, Global, Pipeline for Viral Infections by Stage of Development and Molecule Type, 2016
Figure 19: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Stage of Development, 2016
Figure 20: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Molecule Type, 2016
Figure 21: Viral Infections Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 22: Viral Infections Therapeutics Market, Global, Breakdown of Viral Surface Protein, Immune Mediator and Polymerase Molecular Targets, 2016
Figure 23: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2016
Figure 24: Viral Infections Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006-2016
Figure 25: Viral Infections Therapeutics Market, Global, Clinical Trial Failure and Attrition Rates by Indication and Stage of Development (%), 2006-2016
Figure 26: Viral infections Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 27: Viral Infections Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 28: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Indication and Stage of Development (Months), 2006-2016
Figure 29: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (Months), 2006-2016
Figure 30: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (Months), 2006-2016
Figure 31: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Indication and Stage of Development (Participants), 2006-2016
Figure 32: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Molecule Type and Stage of Development (participants), 2006-2016
Figure 33: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Molecular Target and Stage of Development (participants), 2006-2016
Figure 34: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Indication and Stage of Development (participants), 2006-2016
Figure 35: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Molecule Type and Stage of Development (participants), 2006-2016
Figure 36: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Molecular Target and Stage of Development (participants), 2006-2016
Figure 37: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Sofosbuvir in Combination with Velpatasvir ($bn), 2016-2021
Figure 38: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for TAF ($bn), 2016-2021
Figure 39: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Descovy ($bn), 2016-2021
Figure 40: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Cobicistat in combination with darunavir, emtricitabine and TAF ($bn), 2016-2021
Figure 41: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Beclabuvir Hydrochloride ($bn), 2016-2021
Figure 42: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for V-212 ($m), 2017-2021
Figure 43: Viral Infections Therapeutics Market, Global, Market Size ($bn), 2014-2021
Figure 44: Viral Infections Therapeutics Market, Global, Forecast Revenues for Strongest Commercial Products, 2014-2021
Figure 45: Viral Infections Therapeutics Market, Global, Premium and Generic Market Share ($bn), 2014-2021
Figure 46: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Reverse Transcriptase ($bn), 2014-2021
Figure 47: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A, ($bn), 2014-2021
Figure 48: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting HIV Integrase, ($bn), 2014-2021
Figure 49: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase, ($bn), 2014-2021
Figure 50: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting NS3-4A Protease/Nonstructural Protein 5A, ($bn), 2014-2021
Figure 51: Viral Infections Therapeutics Market, Global, Revenues by Company, 2014-2021
Figure 52: Viral Infections Therapeutics Market, Global, Companies by Compound Annual Growth Rate (CAGR), 2014-2021
Figure 53: Viral Infections Therapeutics Market, Global, Companies by Market Share, 2014-2021
Figure 54: Viral Infections Therapeutics Market, Revenues by Route of Acquisition, 2014-2021
Figure 55: Viral Infections Therapeutics Market, Gilead Sciences Annual Revenues ($bn), 2014-2021
Figure 56: Viral Infections Therapeutics Market, Global, Gilead Sciences Annual Revenues by Product ($m), 2014-2021
Figure 57: Viral Infections Therapeutics Market, Merck Annual Revenues ($bn), 2014-2021
Figure 58: Viral Infections Therapeutics Market, Global, Merck Annual Revenues by Product ($m), 2014-2021
Figure 59: Viral Infections Therapeutics Market, GlaxoSmithKline Annual Revenues ($bn), 2014-2021
Figure 60: Viral Infections Therapeutics Market, Global, GlaxoSmithKline Annual Revenues by Product ($m), 2014-2021
Figure 61: Viral Infections Therapeutics Market, Johnson and Johnson Annual Revenues ($bn), 2014-2021
Figure 62: Viral Infections Therapeutics Market, Global, Johnson and Johnson Annual Revenues by Product ($m), 2014-2021
Figure 63: Viral Infections Therapeutics Market, Bristol-Myers Squibb Annual Revenues ($bn), 2014-2021
Figure 64: Viral Infections Therapeutics Market, Global, Bristol-Myers Squibb Annual Revenues by Product ($m), 2014-2021
Figure 65: Viral Infections Therapeutics Market, Global High-Activity and Late-Stage Pipeline Developers by Company Type, 2006-2016
Figure 66: Viral Infections Therapeutics Market, Global High-Activity and Late-Stage Pipeline Developers by Company Type, 2006-2016
Figure 67: Viral Infections Therapeutic Market, Global, Proportion of Total Company Revenue Attributed to Viral Infection Products, 2014-2021
Figure 68: Viral Infections Therapeutics Market, Global, Licensing Deals by Region, Deal Value and Year, 2006-2016
Figure 69: Viral Infections Therapeutics Market, Global, Licensing Deals by Indication and Deal Value, 2006-2016
Figure 70: Viral Infections Therapeutics Market, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2016
Figure 71: Viral Infections Therapeutics Market, Global, Licensing Deals by Molecule Type, Molecular Target and Deal Value, 2006-2016
Figure 72: Viral Infections Therapeutics Market, Global, Co-development Deals by Region, Deal Value and Year, 2006-2016
Figure 73: Viral Infections Therapeutics Market, Global, Co-development Deals by Indication and Deal Value, 2006-2016
Figure 74: Viral Infections Therapeutics Market, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2016
Figure 75: Viral Infections Therapeutics Market, Global, Co-development Deals by Molecule Type, Molecular Target and Deal Value, 2006-2016 102
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll